M&As wave to galvanize Korean pharmaceutical industry

Published: 2010-05-25 07:00:00

Updated: 2010-05-25 07:00:00

With domestic pharmaceutical markets to be affected by the government’s cash reward plan to doctors and pharmacists who refuse to take rebates and instead purchase medicines at lower prices, local leading drug manufacturers have turned their gaze toward merger and acquisition (M&A) as a major for...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK